Search results
Results From The WOW.Com Content Network
Gabapentin is a prescription medication that was approved by the U.S. Food and Drug Administration in 1993 as a treatment for epilepsy. It works by binding to a type of calcium channel in nerve ...
In the Neurontin case, off-label prescriptions reportedly accounted for 15% of its sales in its first year on the market, 1994, and had grown to 94% of its sales in 2002. That meant that by 2002 ...
Gabapentin, sold under the brand name Neurontin among others, is an anticonvulsant medication primarily used to treat neuropathic pain and also for partial seizures [10] [7] of epilepsy. It is a commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy , postherpetic neuralgia , and central pain . [ 11 ]
Gabapentin could cause ED, desire changes and dysfunction. There’s evidence that gabapentin may affect a man’s ability to reach climax (either by causing PE or delayed climax), especially if ...
Franklin also alleged that physicians and other health care providers were paid illegal kickbacks as a quid pro quo for prescribing Neurontin, including expensive meals, stays at luxury resorts, and cash payments [9] and that Parke-Davis hired ad agencies and marketing firms to produce articles about gabapentin describing the drug's emerging ...
Franklin's suit, filed under the False Claims Act, [11] claimed that Parke-Davis (since acquired by Pfizer) had used fraudulent scientific evidence [11] supported by "tens of thousands of payments" to doctors for "consultations" and "studies" to encourage them to prescribe the drug Neurontin for conditions including migraine, bipolar disorder and attention deficit disorder, even though it was ...
The STEPS trial (an acronym for Study of Neurontin: Titrate to Efficacy, Profile of Safety) was a clinical trial sponsored by Parke-Davis (now Pfizer) to evaluate the anticonvulsant Neurontin. [1] It is notable for being a seeding trial to promote that drug and for contributing to the drug companies loss in the court case Franklin v.
Parke-Davis (2002), the company was accused of illegal marketing practices, including the promotion of off-label uses of its anticonvulsant medication Neurontin. [6] The drug had only been approved for use in patients with epilepsy , but in 2001 over 80% of its $1.8 billion in sales were for indications unapproved by the United States Food and ...